On May 14, Coronado Biosciences, Inc. (NASDAQ:CNDO) announced that it has initiated a Phase 2a clinical trial of TSO (Trichuris suis ova or CNDO-201) for the treatment of pediatric patients with autism spectrum disorder (ASD) at multiple centers in the United States. Coronado Biosciences Inc (NASDAQ:CNDO) weekly performance is 7.74%. On last trading day company shares ended up $1.81. Analysts mean target price for the company is $1.57. Coronado Biosciences Inc (NASDAQ:CNDO) distance from 50-day simple moving average (SMA50) is -1.31%.
On May 15, Aastrom Biosciences, Inc. (NASDAQ:ASTM) the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, reported financial results for the quarter ended March 31, 2014. Aastrom reported a net loss for the quarter ended March 31, 2014 of $6.0 million, or $1.26 per share, compared to $5.5 million, or $3.00 per share, for the same period a year ago. The change in net loss from the prior year is due primarily to the non-cash change in the fair value of warrants and decreases in both research and development and selling, general and administrative expenses. Aastrom Biosciences Inc (NASDAQ:ASTM) shares advanced 9.42% in last trading session and ended the day on $4.53. Its return on assets is -307.00%. Aastrom Biosciences Inc (NASDAQ:ASTM) quarterly performance is 32.07 %.
On May 27, Chimerix, Inc. (NASDAQ:CMRX) a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, announced the completion of an underwritten public offering of 8,395,000 shares of its common stock, including 1,095,000 shares sold pursuant to the full exercise of an option previously granted to the underwriters to purchase additional shares of common stock. All of the shares were offered by Chimerix at a price to the public of $14.22 per share. The gross proceeds to Chimerix from this offering, before deducting underwriting discounts and commissions and other offering expenses payable by Chimerix, were approximately $119.4 million. Chimerix Inc (NASDAQ:CMRX) shares moved up 9.24% in last trading session and was closed at $19.51, while trading in range of $17.71 – $19.80. Chimerix Inc (NASDAQ:CMRX) year to date (YTD) performance is 29.12%.
ArQule, Inc. (NASDAQ:ARQL)’s shares declined 3.10% to $1.41. The company on May 7 announced its financial results for the first quarter of 2014. For the quarter ended March 31, 2014, the Company reported a net loss of $7,141,000 or $0.11 per share, compared to a net loss of $5,775,000, or $0.09 per share, for the first quarter of 2013. At March 31, 2014, the Company had a total of $85,758,000 in cash, equivalents and marketable securities. ArQule, Inc. (NASDAQ:ARQL) ended the last trading day at $1.34. Company weekly volatility is calculated as 8.52% and price to cash ratio as 1.17. ArQule, Inc. (NASDAQ:ARQL) showed a negative weekly performance of -4.96%.
Prima BioMed Ltd (NASDAQ:PBMD) is pleased to announce that the Company has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for Patent Application 11/561,204 “Compositions for immunotherapy and uses thereof” which protects its CVac™ technology; currently in development for ovarian and pancreatic cancer. Prima Biomed Ltd. (NASDAQ:PBMD) weekly performance is 3.13%. On last trading day company shares ended up $1.32. Prima Biomed Ltd. (NASDAQ:PBMD) distance from 50-day simple moving average (SMA50) is 17.92%.